Hytest’s patent portfolio consists of several patents relating to diagnostics of cardiovascular diseases. For further information and inquiries regarding patent licensing, please contact us by writing to: hytest@hytest.fi.
The present invention relates to an immunoassay for detection of BNP, proBNP and fragments thereof. Essentially the assay comprises: a) contacting the antigen with a first antibody specific to a fragment corresponding to amino acids 11-22 of BNP, or to a part of this peptide comprising at least three amino acids of said sequence, to obtain a first order immune complex. b) contacting the first order immune complex obtained at step (a) with a second antibody recognizing said first order immune complex, to obtain a second order immune complex, wherein said antibody is unable to recognize free BNP, proBNP or free first antibody; c) Detecting the second order immune complex.
______________________________________________________________________________________
This invention relates to clinical diagnostics and more particularly to the diagnostics and therapy follow-up of heart muscle necrosis. The invention concerns with a new approach to monitor the condition of heart by leakage of two proteins, troponin I and C, from necrotic heart muscle.
This invention relates to BNP antigen, and particularly to use of a new stable from of said antigen as a standard or calibrator in immunoassays measuring BNP immunoreactivity.
______________________________________________________________________________________
This invention relates to immunoassays, and provides an immunoassay method for detection of unstable antigens. The method is specifically suitable for detection of BNP, proBNP and fragments thereof.
______________________________________________________________________________________
This invention describes a method for diagnosing of cardiovascular diseases, which comprises detection of IGFBP-4 (insulin- like growth factor binding protein-4) fragments in patients’ blood. It provides antibodies as well as epitopes for antibodies, specific to proteolytic fragments (both N- and C-terminal) of IGFBP-4 originated from IGFBP-4 molecule after its cleavage by specific protease PAPP-A. Antibodies could be used for development of immunoassay methods for quantitative or qualitative detection of IGFBP-4 fragments in human blood.
______________________________________________________________________________________